《中国血液透析患者中 SARS-CoV-2 感染的累积率》[《肾脏国际报告》2020 年第 1416 - 1421 页]勘误
Corrigendum to "The Cumulative Rate of SARS-CoV-2 Infection in Chinese Hemodialysis Patients" [Kidney Int. Rep. 2020 1416-1421].
作者信息
Xu Xin, Nie Sheng, Sun Jian, Kong Yaozhong, Liang Min, Li Dongfeng, Ma Tean, Peng Jiaqing, Gao Shikui, Shao Yong, Zha Yan, Peng Gangyi, Ren Chanjun, Huang Ailong, Hou Fan Fan
机构信息
State Key Laboratory of Organ Failure Research; National Clinical Research Center for Kidney Disease, Nanfang hospital, Southern Medical University, Guangzhou, China.
Department of Nephrology, The First People's Hospital of Foshan, Foshan, China.
出版信息
Kidney Int Rep. 2021 Sep;6(9):2525. doi: 10.1016/j.ekir.2021.07.021. Epub 2021 Sep 2.
Abstract
[This corrects the article DOI: 10.1016/j.ekir.2020.07.010.][This corrects the article DOI: 10.1016/j.ekir.2021.07.022.].
摘要
[本文更正了文章DOI：10.1016/j.ekir.2020.07.010。][本文更正了文章DOI：10.1016/j.ekir.2021.07.022。]
相似文献
1
Corrigendum to "The Cumulative Rate of SARS-CoV-2 Infection in Chinese Hemodialysis Patients" [Kidney Int. Rep. 2020 1416-1421].《中国血液透析患者中 SARS-CoV-2 感染的累积率》[《肾脏国际报告》2020 年第 1416 - 1421 页]勘误
Kidney Int Rep. 2021 Sep;6(9):2525. doi: 10.1016/j.ekir.2021.07.021. Epub 2021 Sep 2.
2
Erratum: The Cumulative Rate of SARS-CoV-2 Infection in Chinese Hemodialysis Patients.勘误：中国血液透析患者中新型冠状病毒2感染的累积发生率。
Kidney Int Rep. 2021 Sep;6(9):2526-2531. doi: 10.1016/j.ekir.2021.07.022. Epub 2021 Sep 2.
3
Corrigendum to "Efficacy of evocalcet in previously cinacalcet-treated secondary hyperparathyroidism patients," [ 2021; https://doi.org/10.1016/j.ekir.2021.08.020].《依那卡塞在曾接受西那卡塞治疗的继发性甲状旁腺功能亢进患者中的疗效》勘误，[2021年；https://doi.org/10.1016/j.ekir.2021.08.020] 。
Kidney Int Rep. 2021 Nov 5;6(11):2936-2937. doi: 10.1016/j.ekir.2021.09.011. eCollection 2021 Nov.
4
Corrigendum to Inaba M, Une Y, Ikejiri K, et al. "Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan-A Phase 2 Randomized Trial." . 2022;7:177-188.稻叶真人、宇根洋、池尻健等所著《日本接受血液透析的高磷血症患者中替那帕诺的剂量反应——一项2期随机试验》的勘误。2022年；7：177 - 188。
Kidney Int Rep. 2022 Jul 5;7(7):1729. doi: 10.1016/j.ekir.2022.06.008. eCollection 2022 Jul.
5
Corrigendum to "Narita I. Estimating Growth Rate by a Single Measurement of Kidney Volume in ADPKD." . 2020;5:1383-1384.《多囊肾病中通过单次测量肾脏体积估算生长速率》勘误。2020年；5：1383 - 1384。
Kidney Int Rep. 2021 Feb 10;6(2):552. doi: 10.1016/j.ekir.2020.11.012. eCollection 2021 Feb.
6
Corrigendum to "Transjugular Kidney Biopsy as a Safe Method to Increase the Etiological Diagnosis in Kidney Disease" 2021;6:2535-2536.《经颈静脉肾活检：一种增加肾脏疾病病因诊断的安全方法》勘误 2021 年；6：2535 - 2536。
Kidney Int Rep. 2021 Oct 20;6(12):3095. doi: 10.1016/j.ekir.2021.10.013. eCollection 2021 Dec.
7
Corrigendum to "Vimala, A. Hyponatremia among patients admitted in critical care unit at tertiary care hospitals." . 2020;5:S230.《维玛拉，A. 三级护理医院重症监护病房患者低钠血症》勘误。2020年；5：S230。
Kidney Int Rep. 2020 May 11;5(6):959. doi: 10.1016/j.ekir.2020.05.002. eCollection 2020 Jun.
8
Corrigendum to "Luyckx VA, Cherney DZI, Bello AK. Preventing CKD in Developed Countries." 2020;5:263-277.《“Luyckx VA、Cherney DZI、Bello AK。发达国家慢性肾脏病的预防”》勘误。2020年；5：263 - 277。
Kidney Int Rep. 2020 May 4;5(5):758. doi: 10.1016/j.ekir.2020.03.021. eCollection 2020 May.
9
Corrigendum to "Successful Urine Multiplex Bead Assay to Measure Lupus Nephritis Activity" 2021;6:1949-1960.《用于测量狼疮性肾炎活动度的尿液多重微珠检测法的勘误》2021年；6：1949 - 1960。
Kidney Int Rep. 2021 Aug 31;6(10):2735. doi: 10.1016/j.ekir.2021.08.023. eCollection 2021 Oct.
10
Corrigendum to "Kimura T, Snijder R, Nozaki K. Diagnosis patterns of CKD and anemia in the Japanese population." . 2020;5:694-705.《木村T、斯奈德R、野崎K。日本人群中慢性肾脏病和贫血的诊断模式》勘误。2020年；5:694 - 705。
Kidney Int Rep. 2020 Sep 3;5(9):1614. doi: 10.1016/j.ekir.2020.08.006. eCollection 2020 Sep.
Zotero 插件